Trial Search Results

MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

This research study tests a new medicine for mobilizing stem cells so they can be collected and used for autologous stem cell transplant for treatment of multiple myeloma. MGTA-145, the new medicine, will be given with plerixafor.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Drug: MGTA-145
  • Drug: Plerixafor

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Diagnosis of multiple myeloma per the International Myeloma Working Group (IMWG)
   criteria

   - Eligible for ASCT per institutional guidelines

   - Within one year of start of myeloma therapy

   - Cardiac and pulmonary status sufficient to undergo apheresis and transplantation per
   institutional transplant guidelines.

   - Calculated creatinine clearance > 30 mL/min according to the Modification of Diet in
   Renal Disease (MDRD) formula.

   - Absolute neutrophil count > 1500 x106/L and platelets > 100,000 x106/L

   - Ability to understand and the willingness to sign a written informed consent document.

   - Agreement to use an approved form of contraception for male patients or female
   patients of childbearing potential.

Exclusion Criteria:

   - History of prior stem cell transplant for multiple myeloma or other indications

   - Planned tandem stem cell transplant

   - Prior history of failure to collect HSCs.

   - Liver function tests: Total bilirubin >1.5x upper limit of normal (ULN) in the absence
   of a documented history of Gilbert's syndrome and/or aspartate aminotransferase
   (AST)/alanine aminotransferase (ALT) > 3x ULN.

   - Known allergy to MGTA-145 or plerixafor.

   - Lifetime exposure to lenalidomide or another immunomodulatory drug greater than 6
   cumulative months of treatment i.e more than six 28-day cycles or more than eight
   21-day cycles.

   - Pregnant or lactating women.

Ages Eligible for Study

18 Years - 70 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Khanh Nguyen
650-721-2372